Progenity is a biotechnology business based in the US. Progenity shares (PROG) are listed on the NASDAQ and all prices are listed in US Dollars. Progenity employs 124 staff and has a trailing 12-month revenue of around $1.2 million.
Our top picks for where to buy Progenity stock
How to buy Progenity stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PROG. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Progenity stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Progenity stock price (NASDAQ: PROG)
Use our graph to track the performance of PROG stocks over time.Progenity shares at a glance
Latest market close | $0.69 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $1.07 |
200-day moving average | $1.78 |
Wall St. target price | $4.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.57 |
Is it a good time to buy Progenity stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Progenity price performance over time
Historical closes compared with the close of $0.69 from 2022-07-08
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-03) | N/A |
---|---|
2 years (2022-09-03) | N/A |
3 years (2021-09-07) | 1.07 |
5 years (2019-09-03) | N/A |
Progenity financials
Revenue TTM | $1.2 million |
---|---|
Gross profit TTM | $1.2 million |
Return on assets TTM | -55.95% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market Capitalization | $162.9 million |
TTM: trailing 12 months
Progenity share dividends
We're not expecting Progenity to pay a dividend over the next 12 months.
Progenity overview
Progenity, Inc. , a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc.
Frequently asked questions
What percentage of Progenity is owned by insiders or institutions?Currently 9.163% of Progenity shares are held by insiders and 29.78% by institutions. How many people work for Progenity?
Latest data suggests 124 work at Progenity. When does the fiscal year end for Progenity?
Progenity's fiscal year ends in December. Where is Progenity based?
Progenity's address is: 4330 La Jolla Village Drive, San Diego, CA, United States, 92122 What is Progenity's ISIN number?
Progenity's international securities identification number is: US74319F1075
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question